Abstract
The luteinizing hormone (LH) receptor plays a pivotal role in reproduction. The high-molecular-weight (HMW) human chorionic gonadotropin (hCG) and LH are the endogenous ligands of this receptor and bind to its large N terminus. The present study characterizes the binding of a new low-molecular-weight (LMW) radioligand, [3H]5-amino-2-methylsulfanyl-4-[3-(2-morpholin-4-yl-acetylamino)-phenyl]-thieno[2,3-d]pyrimidine-6-carboxylic acid tert-butylamide (Org 43553), at the LH receptor. Equilibrium saturation and displacement assays were developed and optimized. Specific binding of [3H]Org 43553 to CHO-K1 cell membranes expressing the human LH receptor and a cAMP response element-luciferase reporter gene was saturable with a KD value of 2.4 ± 0.4 nM and a Bmax value of 1.6 ± 0.2 pmol/mg protein. Affinities of five LMW analogs of Org 43553 were determined. All displaced the radioligand competitively, with Ki values ranging from 3.3 to 100 nM. Finally, the potency of these compounds in a cAMP-induced luciferase assay was also determined. There was a high correlation between affinity and potency (r = 0.99; P < 0.0001) of these compounds. In the search for LMW ligands, which bind allosterically to the seven-transmembrane domain of the LH receptor, a HMW radioligand (e.g., 125I-hCG) is not suitable as it is not displaced by a LMW compound. Therefore, [3H]Org 43553, a new radioligand with good binding properties, allows screening for new LMW ligands that mimic the action of the endogenous hormone at the LH receptor.
Footnotes
-
ABBREVIATIONS: LH, luteinizing hormone; hCG, human chorionic gonadotropin; LMW, low molecular weight; BSA, bovine serum albumin; CHO, Chinese hamster ovary; CHOhLHr_luc, human LH receptor and luciferase reporter gene transfected in CHO cells; CRE-luc, cAMP-response-element luciferase reporter gene; GPCR, G protein-coupled receptor; recLH, recombinant luteinizing hormone; PBS, phosphate-buffered saline; Org 43553, 5-amino-2-methylsulfanyl-4-[3-(2-morpholin-4-yl-acetylamino)-phenyl]-thieno[2,3-d]pyrimidine-6-carboxylic acid tert-butylamide; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate; PEI, polyethylenimine.
- Received July 10, 2007.
- Accepted November 7, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|